Geron (GERN) Scheduled to Post Quarterly Earnings on Thursday

Geron (NASDAQ:GERN) will announce its earnings results before the market opens on Thursday, November 7th. Analysts expect the company to announce earnings of ($0.08) per share for the quarter. Persons that are interested in participating in the company’s earnings conference call can do so using this link.

Geron (NASDAQ:GERN) last issued its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.10). The company had revenue of $0.88 million during the quarter, compared to the consensus estimate of $0.34 million. Geron had a negative net margin of 15,990.68% and a negative return on equity of 73.79%. Geron’s revenue for the quarter was up 2941.4% on a year-over-year basis. During the same quarter last year, the company earned ($0.09) earnings per share. On average, analysts expect Geron to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Geron Price Performance

Shares of GERN stock opened at $4.22 on Wednesday. The firm has a fifty day simple moving average of $4.34 and a 200-day simple moving average of $4.30. The company has a market capitalization of $2.54 billion, a PE ratio of -11.81 and a beta of 0.52. Geron has a twelve month low of $1.64 and a twelve month high of $5.34. The company has a current ratio of 3.61, a quick ratio of 3.60 and a debt-to-equity ratio of 0.12.

Wall Street Analyst Weigh In

GERN has been the topic of a number of analyst reports. StockNews.com raised Geron to a “sell” rating in a research report on Monday, August 5th. Leerink Partnrs raised Geron to a “strong-buy” rating in a research report on Monday, September 9th. HC Wainwright started coverage on shares of Geron in a research report on Tuesday. They set a “buy” rating and a $8.00 price target for the company. Leerink Partners started coverage on shares of Geron in a report on Monday, September 9th. They issued an “outperform” rating and a $7.00 price target on the stock. Finally, Needham & Company LLC reissued a “buy” rating and set a $6.00 price objective on shares of Geron in a report on Friday, August 9th. One analyst has rated the stock with a sell rating, one has issued a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $7.05.

Geron Company Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.